Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:57:15.299Z.
Calculation as of: 2026-10-06T16:57:15.299Z.
Quote observation: 2026-10-06T16:55:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f7cc47a755cd2bcf7eb9f00e67443ad18d7371fac0edeabf5a8ccfa0f762fc55
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$1.03B
EV/EBITDA Ratio
N/A
TTM Avg
56.92x
3Y Avg
58.14x
5Y Avg
58.14x
Market Cap
$1.04B
EV/EBITDA Ratio
N/A
TTM Avg
2.11x
3Y Avg
2.11x
5Y Avg
2.11x
Market Cap
$1.04B
EV/EBITDA Ratio
3.54x
TTM Avg
9.11x
3Y Avg
16.07x
5Y Avg
16.78x
Market Cap
$1.03B
EV/EBITDA Ratio
28.03x
TTM Avg
28.85x
3Y Avg
28.85x
5Y Avg
28.85x
Market Cap
$1.05B
EV/EBITDA Ratio
12.94x
TTM Avg
29.00x
3Y Avg
192.84x
5Y Avg
192.84x
Market Cap
$1.00B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$991.81M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | $1.03B | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.03B | N/A | 56.92x | 58.14x | 58.14x |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.04B | N/A | 2.11x | 2.11x | 2.11x |
| Immatics N.V. (IMTX)vs › | $1.03B | N/A | 21.42x | 21.42x | 21.42x |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.04B | 3.54x | 9.11x | 16.07x | 16.78x |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | 28.03x | 28.85x | 28.85x | 28.85x |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 12.94x | 29.00x | 192.84x | 192.84x |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.00B | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $991.81M | N/A | N/A | N/A | N/A |
| IRadimed Corporation (IRMD)vs › | $1.08B | 34.82x | 40.48x | 32.62x | 34.28x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
